While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback